Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2021-05-04 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
NYR Announces New Potent Cholesterol-Lowering Candidates 4 pages 322.4KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Nyrada Inc providing an update on the progress of its Cholesterol-Lowering Program, including medicinal chemistry work, preclinical studies, and plans for Phase I clinical trials. It contains scientific and developmental information about drug candidates, study results, and future plans. There are no financial statements, earnings data, or regulatory filings typical of annual or quarterly reports. It is not a transcript of a call, nor a voting result or management change announcement. The content is focused on research and development progress and corporate updates related to drug development. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as financial reports, earnings releases, or capital updates. The document length (8179 characters) and detailed content confirm it is not a brief report publication announcement or a certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-05-04 English
Change of Registered Office and Principal Place of Business 2 pages 198.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 26 April 2021 about the change of the registered office and principal place of business of Nyrada Inc. It contains no financial data, no discussion of financial results, no regulatory certifications, or detailed report content. The length is only 2741 characters, which is quite short and typical of a brief corporate announcement. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a management or board change announcement but a change of registered office address. This type of announcement is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-25 English
Nyrada Quarterly Activities Report & Appendix 4C 10 pages 450.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report & Appendix 4C' and covers the quarter ending 31 March 2021. It includes detailed updates on the company's research programs, financial summary including cash flow, capital raising activities, and an Appendix 4C cash flow report which is a standard quarterly report required by the ASX for listed entities. The document contains substantive financial data and analysis for the quarter, including cash flows from operating, investing, and financing activities, as well as commentary on the company's progress and outlook. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the correct classification is IR. Q3 2021
2021-04-19 English
Appendix 2A 15 pages 256.0KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, dates of previous announcements (Appendix 3B), and the purpose of the securities issuance. This form is a regulatory announcement related to capital markets activity, specifically the listing or quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The document is a formal regulatory filing announcing the application for quotation of securities, which fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the securities issuance and related transactions, consistent with a capital/financing update filing.
2021-03-29 English
Cleansing Statement 2 pages 201.9KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Cleansing Statement' and references an Appendix 2A lodged previously, which relates to a capital raising program. It includes legal references to the Corporations Act 2001 (Cth) and confirms compliance with disclosure requirements. The document is short (3374 characters) and serves as a notice regarding the issuance of CHESS Depositary Interests (CDIs) without disclosure under certain provisions, which is typical for capital raising or financing updates. There are no financial statements or detailed financial data presented, and it is not an annual or interim report. The content aligns with a Capital/Financing Update rather than a full report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-03-29 English
Change in substantial holding 2 pages 212.5KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder, Noxopharm Limited, in Nyrada Inc. It provides specific numbers of shares/CDIs held before and after the change, along with voting power percentages. There is no financial data, earnings information, or management discussion. The content clearly fits the definition of a 'Major Shareholding Notification' which involves notification of changes in significant share ownership levels crossing thresholds. The document length is short and focused solely on shareholding changes, confirming it is not a full report or announcement of a report publication. Therefore, the correct classification is MRQ (Major Shareholding Notification).
2021-03-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.